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Background: Cognitive impairment is a major contributor to disability and reduced quality 
of life in secondary progressive MS (SPMS). In the 24 month MS-STAT phase 2 trial we 
showed that high dose simvastatin significantly reduced the rate of whole brain atrophy, as 
well demonstrating effects on clinician and patient observed outcome measures. We 
describe here results of  the MS-STAT sub-study, evaluating treatment effect on cognitive 
and neuropsychiatric outcome measures.   
Objectives: 140 patients with SPMS, with Expanded Disability Severity Scales (EDSS) 
scores between 4 and 6.5, were randomised to receive simvastatin (n=70) or placebo 
(n=70). Full cognitive and neuropsychiatric testing was undertaken at study entry, 12 and 
24 months. 
Methods: The following cognitive domains were tested: premorbid IQ; general intellectual 
functioning; verbal and nonverbal memory; semantic memory; visual perceptual function; 
attention, speed of information processing, and working memory (PASAT-3); frontal lobe 
function (frontal assessement battery, FAB). Neuropsychiatric symptoms were assessed 
using the Hamilton Depression Scale and the Neuropsychiatric Inventory Questionnaire. 
Linear mixed models were used to examine how cognitive and neuropsychiatric scores 
changed between baseline, 12 and 24 months and to evaluate the difference in score 
between the placebo and simvastatin group at 12 and 24 months. 
Results: Baseline assessment revealed that nearly half of patients showed impairment on 
frontal lobe function (45%) and on the PASAT-3 (46%). There were also significant 
numbers of patients (up to 33%) with impairment on tests of verbal and nonverbal memory. 
Over the entire trial, the cohort as a whole declined on tests of verbal and non-verbal 
memory. At 24 months, there was a significant difference in FAB scores between the two 
treatment groups, with a 0.24 point increase in the mean FAB score observed in the 
simvastatin-treated group, compared with a decline of 0.92 points in the placebo group: a 
difference of 1.08 ( 95% CI 0.09 to 2.14). No significant treatment effect was observed on 
any other cognitive or neuropsychiatric measures. 
Conclusion: This represents the largest SPMS published cohort to have been studied with 
longitudinal cognitive and neuropsychiatric assessments. Frequent cognitive impairment 
was observed at  study entry, with decline at 24 months observed primarily in episodic 
memory. Although results must be interpreted carefully because of the many variables 
examined, we found that high dose simvastatin significantly improves frontal lobe function, 
adding to our previous observation of a positive treatment effect on brain atrophy rates. 
These results highlight the importance of including detailed cognitive outcome measures 
within progressive MS therapeutic trials. 
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